Latent infection with Epstein-Barr virus (EBV) is associated with several human cancers, including nasopharyngeal cancer. During latent EBV infections, the glycine-alanine repeat (GAr) domain of the EBV nuclear antigen-1 (EBNA1) inhibits translation of EBNA1 mRNA, thereby suppressing the production of antigenic peptides that the human immune system recognises as foreign. Here, Blondel et al. establish a yeast-based assay that recapitulates GAr-mediated suppression of EBNA1 mRNA translation and use it to identify doxorubicin and its active analogues as compounds that specifically interfere with GAr-mediated suppression of translation. Importantly, in mammalian cells, doxorubicin and its analogues stimulate EBNA1 expression in a GAr-dependent manner and overcome the GAr-dependent restriction of antigen presentation. Together, these results validate the yeast-based assay as an effective cell-based screening approach for compounds that interfere with EBV immune evasion and that might, therefore, provide treatments for EBV-related diseases, including cancer. Page 435
Preventing EBV immune evasion Open Access
Preventing EBV immune evasion. Dis Model Mech 1 April 2014; 7 (4): e0201. doi:
Download citation file:
Advertisement
Cited by
Call for papers – In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery

We invite you to submit your latest research to our upcoming special issue: In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery, coordinated by DMM Editor Vivian Li (The Francis Crick Institute, London, UK), alongside Guest Editors Austin Smith (University of Exeter, UK) and Joseph Wu (Stanford University School of Medicine, USA).The deadline for submitting articles is 6 October 2025.
The Company of Biologists Workshops

For the last 15 years, our publisher, The Company of Biologists, has provided an apt environment to inspire biology and support biologists through our Workshops series. Read about the evolution of the Workshop series and revisit JEB's experience with hosting the first Global South Workshop.
Read & Publish Open Access publishing: what authors say

We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review

Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
Propose a new Workshop for 2027

We are currently seeking proposals for Workshops to be held in 2027. As one of the scientific organisers of a The Company of Biologists Workshop, your involvement will be focused on interdisciplinary, cutting-edge science and promoting new partnerships and collaborations. We focus on the logistics. Are you thinking about proposing a topic for one of our Workshops? Apply by Friday 30 May 2025.
Other journals from
The Company of Biologists